Volume : 12, Issue : 08, August- 2025
Title:
FORMULATION AND INVITRO EVALUATION OF FLOATING TABLETS USING TAPENTADOL HCL AS A MODEL DRUG
Authors :
*Mrs.T.Sowmya, Dr.T.Mangilal
Abstract :
The oral route is the predominant and most preferable route for drug delivery, but drug absorption is unsatisfactory and highly variable in the individuals despite excellent in vitro release patterns. Several approaches are currently utilized in the prolongation of the gastric residence times, including floating drug delivery systems, swelling and expanding systems, polymeric bio adhesive systems, modified-shape systems, high-density systems and other delayed gastric emptying devices. Pain is a disorder that everyone experiences. Analgesics having similar effectiveness with improved compliance in comparison to opioids are valuable additions to the analgesic armamentarium. Polymers used in the drug delivery system are of two types Natural and Synthetic based on their origin. Both types of the polymers have some advantages and disadvantages. This results in prolonged gastric retention time of floating forms which improve bioavailability of drug and also improve clinical situations. FDDS is one amongst the GRDF’s used to achieve prolonged gastric residence time. The purpose of writing this review on FDDS was to compile the recent literature with principle mechanism of floatation to achieve gastric retention. The development of FDDS including the physiology and formulation factors affecting gastric retention, classification and formulation, advantages and disadvantages are covered. This also summarizes the in vitro studies to evaluate the performance and application of FDDS.
Keywords: Delayed gastric emptying devices, Analgesics, opioids, Natural and Synthetic Polymers, FDDS and GRDF.
Cite This Article:
Please cite this article in press T.Sowmya et al., Formulation And Invitro Evaluation Of Floating Tablets Using Tapentadol Hcl As A Model Drug., Indo Am. J. P. Sci, 2025; 12(08).
Number of Downloads : 10
References:
1.Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv 2006; 3(2):217-33.
2.Zubedi SS, Mohammed S, Floating tablets and its polymers,Journal of Drug Delivery and Therapeutics. 2018; 8(5-s):16-24.
3.Lachman L, Lieberman HA, The theory and practice of industrial pharmacy, CBS publishers and distributors, special Indian edition, New Delhi. 2009 p. 300,301,317.
4.Vivek K. Pawar, Shaswat Kansal, Garima Garg, Rajendra Awasthi,Deepak Singodia & Giriraj T. Kulkarni (2011) Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems, Drug Delivery, 18:2, 97-110.
5.S.Gopalakrishnan, A. Chenthilnathan, Floating Drug Delivery Systems: A Review Journal of Pharmaceutical Science and Technology Vol. 3 (2), 2011,548-554
6.Suresh karudumpala, Madhusudhana Chetty, Gnanaprakash K, Venkatesh B, Sankar P, A review on bilayer floating tablets, (2013) Int. J. Res. Pharma. Sci., 4(2),354-360.
7.Palavi Pal, Vijaya Sharma, Lalit Singh, A review on floating type gastroretentive drug delivery system et al. IRJP2012,3(4).
8.Shalini Sharma, Mukesh Prashar, Ram Kumar Sahu, Floating Drug Delivery System: Incredible Revolution, Pharmacologyonline 3: 1039-1054(2011).
9.Nikita Dixit, Floating drug delivery system, journal of current pharmaceutical research 2011;7 (1);6-20.
10.Chaturvedi Shashank, Kumari Prabha, Singh Sunil, Agrawal Vipin Kumar, Approaches to increase the gastric residence time: Floating drug delivery systems-A review, Asian journal of pharmaceutical and clinical research, vol 6, issue 3, 2013, 0974-2441.
11.Dewan Roshan Singh, Kusha Nag, Akshaya N. Shetti, and N. Krishnaveni, Tapentadol hydrochloride: A novel analgesic, Saudi J Anaesth. 2013 Jul-Sep; 7(3): 322–326.
12.K Brown MD (Chief Resident)Paul J Christo MD(Assistant Professor)Christopher L Wu MD(Associate Professor), Strategies for postoperative pain management, Elsevier, Volume 18, Issue 4, December 2004, Pages 703-717.
13.W. Jacqueline K wong PharmD PhD1, IpekÖzer-StillmanMS2, Jeffrey D. Miller MS2, Noah A. HaberBA2, Mason W. RussellMAPE2, ShaneKavanaghMSc3, Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain, Elsevier, Volume 32, Issue 10, September 2010, Pages 1768-1781
14.William E. Wade, William J. Spruill, Tapentadol hydrochloride: A centrally acting oral analgesic, Elsevier, Clinical Therapeutics,Volume 31, Issue 12, December 2009, Pages 2804-2818
15.John D Loeser MD Ronald Melzack, Pain: an overview, The Lancet, Volume 353, Issue 9164, 8 May 1999, Pages 1607-1609
16.K.L.Casey, R.Dubner, K.M.Foley, R.H.Gracely, A.E.Reading, Pain measurement: an overview, Elsevier, Volume 22, Issue 1, May 1985, Pages 1-31
17.Mr. Y. Shiva Kumar, M. Rasagna, Dr.T.Mangilal, Preparation and Evaluation of Tapentadol Hydrochloride Solid Lipid Nanoparticles, Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):618-624.
18.W. Schröder, T. M. Tzschentke, R. Terlinden, J. De Vry, U. Jahnel, T. Christoph and R. J. Tallarida, Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia,Journal of Pharmacology and Experimental Therapeutics April 2011, 337 (1) 312-320.